Incyte Corporation

Incyte Corporation is the oncology-and-inflammation biotech leader — Jakafi (ruxolitinib, blockbuster JAK inhibitor for myelofibrosis/polycythemia vera), Opzelura (topical ruxolitinib for atopic dermatitis and vitiligo), and Iclusig plus a specific pipeline. The 2026 story is landing across multiple catalysts.

• The Q2 mechanics were extraordinary: revenue of $1.67B grew ~21% YoY at a 92% gross margin and 27% operating margin, EPS of $3.09 beat consensus of $2.15 by 44%, and $359M of quarterly free cash flow — for a business at just 15.5x TTM PE with 20% ROIC and consensus FY26 EPS of $4.80 putting the forward at ~25x, the mechanical improvement supports the multi-year re-rating.
• The Opzelura EU approval is the specific structural catalyst: Opzelura cream won EU approval for adult moderate atopic dermatitis (first steroid-free topical JAK inhibitor in the EU for AD), backed by Phase 3b TRuE-AD4 hitting both co-primary endpoints — that's the specific TAM-expansion catalyst that supports continued upward multiple pressure, and the CMS-Opzelura Medicaid-line-extension resolution removes a specific reimbursement overhang.
• The tape confirms accelerating trajectory: shares sit at the 77th percentile of the 52-week range, +6.3% vs the 50-day and +17% vs the 200-day, up 23% YTD, up ~80% since Baker Brothers took board chair and Meury became CEO in June 2025 — that's the specific management-transition-plus-mechanical-improvement combination. The 15-insider-event Aug activity is mostly option-linked mechanics.

What extends the accelerating trajectory is the Oct 27 print confirming Opzelura EU launch commentary plus continued Jakafi trajectory; what interrupts it is a specific Opzelura competitive move or a specific Jakafi generic-erosion signal that reveals the multiple can't sustain the current growth trajectory.